Discussion
AP-101, an experimental treatment being developed by AL-S Pharma for amyotrophic lateral sclerosis (ALS), may help patients preserve their body weight compared with a placebo, potentially indicating better clinical outcomes as the disease progresses. These findings come from a post-hoc analysis of AP101-02 (NCT05039099), a completed Phase…